Probiotics Alleviate Chemotherapy-Associated Intestinal Mucosal Injury via the TLR4–NFκB Signaling Pathway
Xiaochong Li,Bowen Hu,Jiachen Zheng,Zhiyong Pan,Yuxiang Cai,Mingjuan Zhao,Xiaoqing Jin,Zhi-Qiang Li
DOI: https://doi.org/10.2147/DDDT.S403087
2023-07-26
Abstract:Xiaochong Li, 1, &ast Bowen Hu, 1, &ast Jiachen Zheng, 2, 3 Zhiyong Pan, 1 Yuxiang Cai, 4 Mingjuan Zhao, 1 Xiaoqing Jin, 2 Zhi-Qiang Li 1 1 Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, People's Republic of China; 2 Emergency Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, People's Republic of China; 3 The Second Clinical School, Wuhan University, Wuhan, Hubei, 430071, People's Republic of China; 4 Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaoqing Jin; Zhi-Qiang Li, Email ; Introduction: Temozolomide (TMZ) induces intestinal mucosa injury that cannot be fully counteracted by supportive treatment. Probiotics regulate gut microbial composition and the host immune system and may alleviate this side effect. We aimed to investigate the potential and mechanism of Lactobacillus rhamnosus GG (LGG) in relieving intestinal mucosal injury induced by TMZ. Methods: Glioblastoma mice were divided into four groups: CON (control), LGG (10 9 CFU/mL, treated for 7 days), TMZ (50 mg/kg·d, treated for 5 days), LGG+TMZ (LGG for 7 days and TMZ subsequently for 5 days). Body weight, food intake, and fecal pH were recorded. Intestinal tissue samples were collected 1 day after the end of TMZ treatment. Degree of damage to intestine, expression of IL1β, IL6, TNFα, and IL10 in jejunum were determined. Levels of tight-junction proteins (ZO1, occludin), TLR4, IKKβ, IκBα, and P65 with their phosphorylation in jejunum were measured. Results: Decreases in body weight, food intake, spleen index in the TMZ group were mitigated in the LGG+TMZ group, and the degree of intestinal shortening and damage to jejunum villus were also alleviated. The expression of tight-junction proteins in the LGG+TMZ group was significantly greater than that in the TMZ group. IκBα in intestinal tissue significantly decreased in the TMZ group, phos–IKKβ and phos-P65 increased compared to the CON group, and LGG reversed such changes in IκBα and phos-P65 in the LGG+TMZ group. Intestinal inflammatory cytokines were significantly increased in the TMZ group, but lower in the LGG+TMZ group. Moreover, expression of TLR4 in LGG group was significantly lower than that in the CON group. LGG inhibited the rise of TLR4 after TMZ in the LGG+TMZ group compared to the TMZ group. Conclusion: LGG inhibits the activation of the TLR4–NFκB pathway and alleviates intestinal mucosal inflammation induced by TMZ, thereby protect the jejunum villi and mucosal physical barrier. Keywords: Lactobacillus rhamnosus GG, temozolomide, intestinal mucosal injury, TLR4, NFκB Intestinal mucosal injury can accompany the entire cycle of chemotherapy. The incidence of enteral mucositis is 50%–100% of patients receiving chemotherapy, depending on the type and regimen of chemotherapy drugs. 1 Temozolomide (TMZ) is a first-line chemotherapeutic agent for the treatment of malignant intracranial tumors 2 that induces the alkylation of DNA, and thus the autophagy or apoptosis of tumor cells. However, it also induces the apoptosis of intestinal mucosal epithelial cells, thus destroying the intestinal mucosal barrier and triggering inflammation. 3 Briefly, chemotherapy-associated intestinal mucositis occurs in five pathological stages: initiation, primary damage response, signal amplification, ulceration, and healing. 4 Activation of the NFκB signaling pathway and the synthesis of proinflammatory cytokines are thought to be key to the initiation and signal-amplification stage. 5,6 The TLR4–NFκB signaling pathway can be continuously activated by various damage-associated molecular patterns produced by dead or injured intestinal epithelial cells, including HMGB1, ROS, and LPS from the enteric cavity, which can induce the gene transcription of proinflammatory cytokines, such as TNFα, IL1β, and IL6, thus promoting the inflammatory cascade and disrupting the intestinal mucosa. 7,8 Intestinal mucositis induced by TMZ can interfere with patients' treatment adherence to avoid unbearable symptoms, including nausea, vomiting, anorexia, stomachache, diarrhea, and constipation. 9 Current supportive therapy (such as with 5-hydroxytryptamine receptor antagonists, glucocorticoids, agents affecting gastrointestinal motility, and antibiotics), 10 however, can only relieve the symptoms to a moderate degree. Some 60% and 37% patients, respectively, still suffer from naus -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal